GLATOPA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GLATOPA (GLATOPA).
Glatiramer acetate (GLATOPA) is a mixture of synthetic polypeptides that alters immune processes by inducing and expanding T-helper 2 (Th2) regulatory cells, which suppress pro-inflammatory T-helper 1 (Th1) cells. It also competes with myelin basic protein for binding to major histocompatibility complex (MHC) molecules, thereby modulating antigen presentation and reducing autoimmune attack on myelin.
| Metabolism | Glatiramer acetate is rapidly hydrolyzed locally at the injection site by proteases; systemic metabolism is minimal. No specific cytochrome P450 enzymes are involved. |
| Excretion | Glatiramer acetate is extensively metabolized locally at the injection site and systemically by proteolysis. The metabolites are eliminated primarily via renal excretion (approximately 70%) and biliary/fecal excretion (approximately 30%). Less than 1% is excreted unchanged. |
| Half-life | The terminal elimination half-life of glatiramer is approximately 1.5–2 hours after subcutaneous administration. This short half-life is due to rapid proteolytic degradation; however, the clinical effect persists for days due to immunological mechanisms. |
| Protein binding | Glatiramer acetate is not significantly bound to plasma proteins (<10%). It is composed of synthetic polypeptides that do not bind appreciably to albumin or other proteins. |
| Volume of Distribution | The volume of distribution (Vd) is not well-defined due to extensive metabolism; however, estimates suggest a Vd of approximately 2–3 L/kg, indicating wide distribution into tissues beyond plasma volume. |
| Bioavailability | Subcutaneous: Bioavailability is approximately 30–40% due to extensive local metabolism and degradation. No intravenous administration is used clinically; oral bioavailability is negligible. |
| Onset of Action | Subcutaneous: The clinical onset of action may be observed as early as 2–3 months after initiation of therapy, but maximal benefit may take 6–12 months. No immediate clinical effect is seen. |
| Duration of Action | The duration of action is approximately 24–48 hours based on immunomodulatory effects, but the dosing interval is typically 3 times per week (e.g., 40 mg/mL) or daily (20 mg/mL) to maintain clinical efficacy. The effect wanes if treatment is discontinued. |
20 mg subcutaneously once daily.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR ≥15 mL/min; insufficient data for GFR <15 mL/min. |
| Liver impairment | No dose adjustment recommended for Child-Pugh A, B, or C; monitor hepatic function. |
| Pediatric use | Not established in patients <18 years of age. |
| Geriatric use | No specific dose adjustment; use with caution due to higher risk of injection-site reactions. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GLATOPA (GLATOPA).
| Breastfeeding | Not known if excreted in human milk. Molecular weight suggests possible excretion. M/P ratio unknown. Caution advised; benefits vs risks considered. |
| Teratogenic Risk | Glatiramer acetate is not teratogenic in animal studies at doses up to 37 times the human dose. No adequate human data; risk cannot be excluded. Use only if clearly needed. |
| Fetal Monitoring | Standard prenatal care; no specific monitoring required for glatiramer acetate exposure. |
■ FDA Black Box Warning
No FDA black box warning exists for glatiramer acetate.
| Serious Effects |
["Known hypersensitivity to glatiramer acetate or mannitol."]
| Precautions | ["Immediate post-injection reaction (e.g., flushing, chest tightness, palpitations, anxiety, dyspnea) may occur, typically self-limiting within 15-30 minutes.","Lipoatrophy and skin necrosis at injection sites; proper injection technique and rotation are recommended.","Potential for immune-mediated reactions (e.g., anaphylaxis, urticaria, angioedema)."] |
Loading safety data…
| Fertility Effects | Animal studies show no impairment of fertility at doses up to 36 times human dose. Human data limited; no known adverse effects. |